Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Mar 30;16(3):e57276.
doi: 10.7759/cureus.57276. eCollection 2024 Mar.

Haloperidol-Induced Neuroleptic Malignant Syndrome: A Case Report

Affiliations
Case Reports

Haloperidol-Induced Neuroleptic Malignant Syndrome: A Case Report

Jordan P Fader et al. Cureus. .

Abstract

Neuroleptic malignant syndrome (NMS) is a severe reaction to antipsychotic medications characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction. Here, we describe the case of a 58-year-old female who presented with altered mental status two days after open reduction and internal fixation of the hip. A rapid response team was called when the patient appeared agitated with increased respiratory demand. After being intubated and moved to the ICU, she became febrile and rigid. A preliminary diagnosis of metabolic encephalopathy of unknown origin was made. Before being transported to the ICU, the patient was given multiple haloperidol doses in addition to her continued at-home medication, paroxetine, for major depressive disorder. The differential diagnosis included a workup for NMS, serotonin syndrome, and infectious processes. Once NMS was determined as the most likely etiology, all antipsychotic and serotonergic medications were discontinued. Then dantrolene and amantadine were administered, which resulted in clinically significant improvement. This case report demonstrates the importance of early identification of and intervention for NMS.

Keywords: antipsychotics; haloperidol; neuroleptic agents; neuroleptic malignant syndrome; nms.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. The patient's daily maximum body temperature and daily total haloperidol dosing by postoperative day

References

    1. Neuroleptic malignant syndrome: a review for neurohospitalists. Berman BD. Neurohospitalist. 2011;1:41–47. - PMC - PubMed
    1. Neuroleptic malignant syndrome. Strawn JR, Keck PE, Caroff SN. Am J Psychiatry. 2007;164:870–876. - PubMed
    1. American Psychiatric Association. Washington, DC: American Psychiatric Publishing; 2022. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision.
    1. Aujla RS, Patel R. StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. Creatine phosphokinase. - PubMed
    1. Rahman S, Marwaha R. StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. Haloperidol. - PubMed

Publication types

LinkOut - more resources